¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"tissue thromboplastin inhibition time"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 3
¿µ¹® subcutaneous tissue, subcutis ÇÑ±Û ÇÇÇÏÁ¶Á÷
¼³¸í   
  ÇǺο¡¼­ ÁøÇÇÀÇ ¾Æ·§ºÎºÐÀ» ¸»ÇÔ. ¿©±â¿¡´Â Áö¹æÁ¶Á÷ÀÌ ¸¹´Ù. ±â´ÉÀº ¿­ÀÇ °Ý¸®, Ãæ°ÝÈí¼ö, ¿µ¾çÀúÀå¼Ò µîÀÌ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • retroactive inhibition
    ¿ªÇà±â¾ï¾ïÁ¦, ¾Õ±â¾ï¾ïÁ¦
  • reversible inhibition
    °¡¿ª¾ïÁ¦
  • selective inhibition
    ¼±ÅþïÁ¦
  • areolar tissue
    ¼º±ÙÁ¶Á÷
  • adipose tissue
    Áö¹æÁ¶Á÷
  • compact tissue
    Ä¡¹ÐÁ¶Á÷
  • connective tissue
    °áÇÕÁ¶Á÷
  • connective tissue cell
    °áÇÕÁ¶Á÷¼¼Æ÷
  • connective tissue disease
    °áÇÕÁ¶Á÷º´
  • connective tissue fiber
    °áÇÕÁ¶Á÷¼¶À¯
  • connective tissue nevus
    °áÇÕÁ¶Á÷¸ð¹Ý
  • elastic tissue
    ź·ÂÁ¶Á÷
  • epithelial tissue
    »óÇÇÁ¶Á÷
  • erectile tissue
    ¹ß±âÁ¶Á÷
  • granulation tissue
    À°¾ÆÁ¶Á÷
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • acquisition time
    ȹµæ½Ã°£
  • bleeding time
    ÃâÇ÷½Ã°£
  • clot retraction time
    ÇǶ±µÞ´ç±è½Ã°£, Ç÷º´ÅðÃà½Ã°£
  • coagulation time
    ÀÀ°í½Ã°£
  • colonic transit time
    ´ëÀåÅë°ú½Ã°£
  • diastolic filling time
    È®Àå±âÃæ¸¸½Ã°£
  • diffusion time
    È®»ê½Ã°£
  • expiratory pause time
    ³¯¼ûÈĽ¬´Â½Ã°£, È£±âÈÄÈÞÁö½Ã°£
  • expiratory phase time
    ³¯¼û½Ã°£, È£±â½Ã°£
  • exposure time
    ³ëÃâ½Ã°£, Æø·Î½Ã°£
  • gastric emptying time
    À§¹èÃâ½Ã°£
  • inspiratory pause time
    µé¼ûÈĽ¬´Â½Ã°£, Èí±âÈÄÈÞÁö½Ã°£
  • inspiratory phase time
    µé¼û½Ã°£, Èí±â½Ã°£
  • latent time
    Àẹ½Ã°£
  • maximum phonation time
    ÃÖÀå¹ß¼ºÁö¼Ó½Ã°£
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • presynaptic inhibition
    ¿¬Á¢Àü¾ïÁ¦, ½Ã³À½ºÀü¾ïÁ¦
  • reciprocal inhibition
    »ó¹Ý¾ïÁ¦, »óÈ£¾ïÁ¦
  • recurrent inhibition
    ȸ±Í¾ïÁ¦
  • reflex inhibition ileus
    ¹Ý»ç¾ïÁ¦Ã¢ÀÚ¸·ÈûÁõ
  • retroactive inhibition
    ¿ªÇà±â¾ï¾ïÁ¦, ¾Õ±â¾ï¾ïÁ¦
  • reversible inhibition
    °¡¿ª¾ïÁ¦
  • selective inhibition
    ¼±ÅþïÁ¦
  • migration inhibition test
    À̵¿¾ïÁ¦°Ë»ç, À̵¿ÀúÁö°Ë»ç
  • reciprocal inhibition psychotherapy
    »óÈ£¾ïÁ¦Á¤½Å¿ä¹ý
  • acute normal tissue effect
    Á¤»óÁ¶Á÷±Þ¼º¿µÇâ
  • adipose tissue
    Áö¹æÁ¶Á÷
  • tissue antibody
    Á¶Á÷Ç×ü
  • tissue biopsy
    Á¶Á÷»ý°Ë
  • compact tissue
    Ä¡¹ÐÁ¶Á÷
  • connective tissue
    °áÇÕÁ¶Á÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • prechondral tissue
    Dz¿¬°ñÁ¶Á÷
  • primitive connective tissue
    ¿ø½Ã°áÇÕÁ¶Á÷(¡­Ì¿ùêðÚòÄ) °£¿±(Êàç¨) .
  • regular connective tissue
    ±ÔÄ¢¼º °áÇÕÁ¶Á÷, Á¤Çü°áÇÕÁ¶Á÷(ïáû¡Ì¿ùêðÚòÄ).
  • renewal tissue
    Àç»ýÁ¶Á÷
  • HIT= hemagglutination inhibition test
    Ç÷±¸ÀÀÁý¾ïÁ¦½ÃÇè.
  • Internal inhibition
    ³»ºÎ¾ïÁ¦(Үݻåäð¤)
  • Lateral inhibition
    ÃøºÎ¾ïÁ¦(ö°Ý»åäð¤)
  • PETINIA => particle-enhanced turbidimetric inhibition immunoassay
    ÀÔÀÚÁõ´ëºñʾïÁ¦¸é¿ªÃøÁ¤(¹ý)
  • afferent inhibition
    ±¸½É¼º ¾ïÁ¦(Ï´ãýàõåäð¤)
  • agar gel precipitin inhibition test
    ÇÑõ°Öħ°­¼Ò ÀúÁö½ÃÇè(¡­ ˽áÈðæò­ãËúÐ).
  • agglutination inhibition test
    ÀÀÁý¾ïÁ¦½ÃÇè(¡­åäð¤ãËúÐ).
  • allogen(a)ic inhibition
    µ¿Á¾¼¼Æ÷ÀúÁö(¡­á¬øàðæò­).
  • antidromic inhibition
    ¿ª¹æÇ⼺ ¾ïÁ¦ (¡­åäð¤)
  • group Ia inhibition
    ¥°a¤ÇϹA.
  • group Ia inhibition
    ¥°a±º¾ïÁ¦(ÏØàéë«).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • colony inhibition test
    Áý¶ôÇü¼º ÀúÁö½ÃÇè, ¼¼Æ÷±ºÇü¼º ÀúÁö½ÃÇè
  • competitive antagonism/inhibition
    °æÀïÀû ±æÇ×/¾ïÁ¦.
  • competitive inhibition
    °æÀïÀû ¾ïÁ¦, °æÇÕ¼º ¾ïÁ¦(Ìæùêàõåäð¤).
  • competitive inhibition
    °æÇÕÀúÇØ(ÌæùêîÁúª).
  • competitive inhibition
    °æÀïÀû¾ïÁ¦
  • competitive inhibition
    °æÀïÀû¾ïÁ¦
  • complement fixation inhibition test
    º¸Ã¼°íÁ¤ÀúÇØ½ÃÇè(ÜÍô÷ͳïÒîÁúªãËúÐ).
  • complement fixation inhibition test
    º¸Ã¼°áÇÕÀúÇØ½ÃÇè(ÜÍô÷Ì¿ùêîÁúªãËúÐ).
  • conditioned inhibition
    Á¶°ÇÈ­¾ïÁ¦(ðÉËìûùåäð²)
  • contact inhibition
    Á¢ÃËÀúÁö
  • density dependent inhibition
    ¹ÐµµÀÇÁ¸ ÀúÇØ.
  • descending inhibition
    ÇÏÇà¾ïÁ¦(ù»ú¼åäð¤)
  • differential inhibition
    °¨º°¾ïÁ¦(~¾ïÁ¦)
  • enzyme inhibition
    È¿¼Ò¾ïÁ¦.
  • factor, macrophage migration inhibition
    ´ë½Ä¼¼Æ÷ À¯ÁÖÀúÁöÀÎÀÚ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Connective tissue cells
    °áÇÕÁ¶Á÷¼¼Æ÷
    [¿¾ ¿ë¾î] °áÇÕÁ¶Á÷¼¼Æ÷
  • Myeloid tissue
    °ñ¼öÁ¶Á÷
    [¿¾ ¿ë¾î] °ñ¼ö¾çÁ¶Á÷
  • Myeloid tissue
    °ñ¼öÁ¶Á÷ [»À¼ÓÁúÁ¶Á÷]
    [¿¾ ¿ë¾î] °ñ¼ö¾çÁ¶Á÷
  • Lymphoid tissue
    ¸²ÇÁÁ¶Á÷
    [¿¾ ¿ë¾î] ÀӯľçÁ¶Á÷
  • Lymphoid tissue
    ¸²ÇÁÁ¶Á÷
    [¿¾ ¿ë¾î] ÀÓÆÄÁ¶Á÷
  • Osteogenic tissue
    »À¹ß»ýÁ¶Á÷
    [¿¾ ¿ë¾î] Á¶°ñÁ¶Á÷
  • Bone tissue
    »ÀÁ¶Á÷
    [¿¾ ¿ë¾î] °ñÁ¶Á÷
  • Epithelioid tissue
    »óÇǸð¾çÁ¶Á÷
    [¿¾ ¿ë¾î] »óÇǾçÁ¶Á÷
  • Pigment connective tissue
    »ö¼Ò°áÇÕÁ¶Á÷
    [¿¾ ¿ë¾î] »ö¼ÒÁ¶Á÷
  • Reticulofibrous bone tissue
    ¼¼¸Á¼¶À¯»ÀÁ¶Á÷
    [¿¾ ¿ë¾î] ¼¼¸Á¼¶À¯¼º°ñÁ¶Á÷
  • Connective tissue of endometrium
    ÀڱüӸ·°áÇÕÁ¶Á÷
    [¿¾ ¿ë¾î] Àڱ󻸷°áÇÕÁ¶Á÷
  • Subserous tissue
    À帷¹ØÁ¶Á÷
    [¿¾ ¿ë¾î] À帷ÇÏÁ¶Á÷
  • Submucous tissue
    Á¡¸·¹ØÁ¶Á÷
    [¿¾ ¿ë¾î] Á¡¸·ÇÏÁ¶Á÷
  • Mucous connective tissue
    Á¡¾×°áÇÕÁ¶Á÷
    [¿¾ ¿ë¾î] Á¡¾×°áÇÕÁ¶Á÷
  • Osteoid tissue
    Dz»ÀÁ¶Á÷
    [¿¾ ¿ë¾î] °ñ¾çÁ¶Á÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • high-temperature-short-time method
    °í¿Â ´Ü½Ã°£¹ý(ÍÔè®Ó­ãÁÊàÛö)
  • mean generation time
    Æò±Õ¼¼´ë±â°£(øÁгá¦ÓáÑ¢Êà)
  • recovery time
    ȸ¼ö ½Ã°£(üÞâ¥ãÁÊà)
  • relaxation time
    ÀÌ¿Ï ½Ã°£(ì¬èÐãÁÊà)
  • residence time
    µ¿°Å ½Ã°£(ÔÒËÜãÁÊà)
  • resolving time
    "ºÐ¸®½Ã°£, ÇØ»ó½Ã°£"
  • retention time
    ¸Ó¹«¸§ ½Ã°£
  • rotational relaxation time
    ȸÀü À̿Ͻð£(üÞï®ì¬èÐãÁÊà)
  • thermal death time
    ¿­»ç½Ã°£ (æðÞÝãÁÊà)
  • time constant
    ½Ã°£»ó¼ö (ãÁÊàßÈâ¦)
  • time constant of a reaction
    ¹ÝÀÀ ½Ã°£»ó¼ö (ÚãëëãÁÊàßÈâ¦)
  • time factor effect
    ½Ã°£ÀÎÀÚ È¿°ú (ãÁÊàì×í­üùÍý)
  • transient time
    °úµµ±â ½Ã°£(ΦԤѢãÁÊà)
  • turnover time
    Àüȯ½Ã°£(ï®üµãÁÊà)
  • zero time binding DNA
    ¿µ½Ã(çÍãÁ) °áÇÕ(Ì¿ùê) DNA
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • tissue characterization
    Á¶Á÷Ư¼º°¨º°
  • tissue contrast
    Á¶Á÷´ëÁ¶µµ
  • tissue culture
    Á¶Á÷¹è¾ç
  • tissue interaction
    Á¶Á÷°£ÀÇ »óÈ£ÀÛ¿ë
  • acquisition time
    ȹµæ½Ã°£
  • arm to lung time test
    ÆÈÆó¼øÈ¯½Ã°£½ÃÇè
  • correlation time
    »ó°ü½Ã°£
  • data acquisition time
    ÀÚ·áȹµæ½Ã°£
  • delay time
    Áö¿¬½Ã°£
  • diffusion time
    È®»ê½Ã°£
  • doubling time
    ¹è°¡½Ã°£
  • echo time [=TE]
    ¿¡Äڽð£
  • elapsed time
    °æ°ú½Ã°£
  • exposure time
    ³ëÃâ½Ã°£, Á¶ ½Ã°£
  • fast time constant circuit
    °í¼Ó½Ã°£°íÁ¤È¸·Î
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
aPTT activated Partial Thromboplastin Time
PTT Partial Thromboplastin Time
APTT, aPTT activated partial thromboplastin time
KPTT kaolin partial thromboplastin time
ptt partial thromboplastin time
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
HAI Haemagglutination Inhibition
HI Haemagglutination Inhibition
HI Haemagglutination inhibition test
HIT Hemagglutination inhibition test
HLI Hemolysis inhibition
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • chair time
    Áø·á ½Ã°£, Ä¡·á ½Ã°£
    ȯÀÚ°¡ Áø´Ü ¹× Ä¡·á ¹Þ±â À§ÇÑ ½Ã°£.
  • change over time
    ½Ã°£¿¡ µû¸¥ º¯È­
  • coagulation time
    ÀÀ°í ½Ã°£
  • contact time
    Á¢ÃË ½Ã°£
  • correlation time
    »ó°ü ½Ã°£
  • doubling time
    ¹è°¡ ½Ã°£
  • echo time
    ¿¡ÄÚ ½Ã°£
  • exposure time per session
    ´ÜÀ§´ç ³ëÃ⠽ð£
  • fast time constant circuit
    °í¼Ó ½Ã°£ °íÁ¤ ȸ·Î
  • first-time dental patient
    óÀ½ ³»¿øÇÑ È¯ÀÚ
  • hardening time
    °æÈ­ ½Ã°£
    Ä¡°ú¿ë ÀλóÀç ¶Ç´Â ¼®°í°¡ µüµüÇÏ°Ô ±»´Âµ¥ °É¸®´Â ½Ã°£.
  • heating and cooling temperature-place-time profile
    °¡¿­ ¹× ³Ã°¢ ¿Âµµ-À§Ä¡-½Ã°£ Çü
  • inversion time
    ¿ªÀü ½Ã°£
  • left ventricular ejection time
    Á ½É½Ç ±¸Ç÷ ±â°£
  • mixing time
    ±³¹Ý ½Ã°£, È¥ÇÕ ½Ã°£
    µÎ °¡Áö ÀÌ»óÀÇ Àç·á¸¦ È¥ÇÕÇÒ ¶§ ¼Ò¿äµÇ°Å³ª ÁöÄÑ¾ß ÇÏ´Â ½Ã°£À¸·Î, Ä¡°ú ¿µ¿ª¿¡¼­´Â ¼®°í Àç·á, ½Ã¸àÆ®, ¼öÁö, ÀλóÀç, ¸Å¸ôÀç µî¿¡¼­ ÁؼöµÇ¾î¾ß ÇÒ ½Ã°£. Àç·áÀÇ ¹°¸®Àû ¼ºÁú¿¡ ¿µÇâÀ» ÁØ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
proactive inhibition The state or process hypothesised to account for poorer learning rate for elements later in a series as compared to the learning rate for elements coming earlier in a series.
(12 Dec 1998)
product inhibition Inhibition of an enzyme activity by a product of the reaction catalyzed by that enzyme.
(05 Mar 2000)
selective inhibition <chemistry> Inhibitor that occupies the active site of an enzyme or the binding site of a receptor and prevents the normal substrate or ligand from binding.
at sufficiently high concentration of the normal ligand inhibition is lost: the Km is altered by the competitive inhibitor, but the Vmax remains the same.
(05 Jan 1998)
noncompetitive inhibition <chemistry> A form of enzyme inhibition which cannot be reversed by increasing the amount of substrate in the reaction.
(09 Oct 1997)
substrate inhibition Inhibition of an enzyme activity by a substrate of the reaction catalyzed by that enzyme; often, this type of inhibition occurs at elevated substrate levels in which the substrate is binding to a second, non-active site on the enzyme.
(05 Mar 2000)
nonreciprocal contact inhibition <cell biology> Collision behaviour between different cell types in which one cell shows contact inhibition of locomotion and the other does not. An example is the interaction between sarcoma cells and fibroblasts (the former not being inhibited).
(18 Nov 1997)
density dependent inhibition of growth <cell culture> The phenomenon exhibited by most normal (anchorage dependent) animal cells in culture that stop dividing once a critical cell density is reached.
The critical density is considerably higher for most cells than the density at which a monolayer is formed, for this reason, most cell behaviourists prefer the term density dependent inhibition of growth as this avoids any confusion with contact inhibition of locomotion, a totally different phenomenon that is contact dependent.
(12 Jan 1998)
inhibition 1. Arrest or restraint of a process.
2. <psychology> The interference with or prevention of a behavioural or verbal response even though the stimulus for that response is present; in psychoanalysis the unconscious restraining of an instinctual process.
Origin: L. Inhibere = to restrain, habere = to hold
(04 Jul 1999)
inhibition factor <growth factor> A soluble, nondialysable factor that is produced by sensitised lymphocytes following exposure to a specific antigen. It inhibits macrophage migration and causes adherence.
It was originally defined on the basis of inhibition of emigration of mononuclear cells from capillary (haematocrit) tubes, more recently a 13 kD protein with migration inhibitory activity has been isolated.
Acronym: MIF
Synonym: inhibition factor.
(22 Sep 2002)
end product inhibition <biochemistry, physiology> The process of the end product of a particular metabolic reaction inhibiting an allosteric enzyme involved in that reaction as the reaction starts again, thus breaking the reaction cycle.
(09 Oct 1997)
enzyme inhibition theory of narcosis That narcotics inhibit respiratory enzymes by suppression of the formation of high energy phosphate bonds within the cell.
(05 Mar 2000)
uncompetitive inhibition An inhibitory effect on a metabolic function, such as an enzyme, not based on competition for the binding site of the naturally occurring substrate, but on a different effect on the molecule whose function is being inhibited.
(05 Mar 2000)
feedback inhibition <biochemistry, physiology> The process of the end product of a particular metabolic reaction inhibiting an allosteric enzyme involved in that reaction as the reaction starts again, thus breaking the reaction cycle.
(09 Oct 1997)
zone of inhibition <microbiology> The area of no bacterial browth around an antimicrobial agent in the disk-diffusion test.
(09 Oct 1997)
lateral inhibition A simple form of information processing. The classic example is found in the eye, whereby ganglion cells are stimulated if photoreceptors in a well defined field are illuminated, but their response is inhibited if neighbouring photoreceptors are excited (an on field/off surround cell) or vice versa an off field/on surround cell. The effect of lateral inhibition is to produce edge or boundary sensitive cells and to reduce the amount of information that is sent to higher centres, a form of peripheral processing.
(18 Nov 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • time
    ½Ã°£,°èÀý,(º¹¼ö)½Ã´ë,-ȸ(¹è)
  • Central (Standard) Time
    ÁߺΠǥÁؽÃ(G.M.T.º¸´Ù 6½Ã°£ ´ÊÀ½)
  • Double Summer Time
    ÀÌÁß ¼­¸ÓŸÀÓ(Ç¥Áؽ𣺸´Ù 2½Ã°£ ºü¸§)
  • Eastern Standard time
    µ¿ºÎ Ç¥ÁؽÃ(ij³ª´Ù µ¿ºÎ,¹Ì±¹ µ¿ºÎ,¿À½ºÆ®·¹Àϸ®¾Æ µ¿¹«)
  • Father Time
    ½Ã°£ ÇҾƹöÁö
  • Greenwich (Mean(Civil)time
    ±×¸®´ÏÄ¡ Ç¥ÁؽÃ
  • Greenwich Mean Time
    ±×¸®´ÏÄ¡ Ç¥ÁؽÃ
  • Hawaii time
    =Hawaiian Standard TimeÇÏ¿ÍÀÌ Ç¥ÁؽÃ(GMEº¸´Ù 10½Ã°£ ´Ê°í ½Ã°£´ë´Â Alaska Time¿Í °°À½
  • Pacific(Standard) Time
    (¹Ì±¹ÀÇ) ÅÂÆò¾ç Ç¥ÁؽÃ
  • T-time
    ·ÎÄÏ ¹ß»ç ½Ã°£
  • Time Square
    New York ½ÃÀDZØÀå°¡
  • access time
    È£Ãâ½Ã°£(±â¾ï ÀåÄ¡¿¡ Á¤º¸¸¦ ±â·Ï,ÇØµ¶ÄÉ Çϱâ À§ÇÑ ½Ã°£);ÄÄÇ»ÅÍ¿ë¾î
  • apparent time
    (ÇØ½Ã°èµîÀÇ)žçÀÇ À§Ä¡·Î ÃøÁ¤Çϴ½ð£
  • atomic time clock
    ¿øÀÚ ¿¬´ë ½Ã°è
  • atonic time clock
    ¿øÀÚ¿¬´ë
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á